Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Dec 18, 2008	VAGELOS P ROY Director Trans History: 742	Director	Form 4	Other acquisition or disposition	--	--	1,822
Dec 18, 2008	VAGELOS P ROY Director Trans History: 742	Director	Form 4	Other acquisition or disposition	--	--	114,309
Dec 18, 2008	YANCOPOULOS GEORGE Director, EVP, CSO, & Pres Regn Res Labs Trans History: 673	Director, EVP, CSO, & Pres Regn Res Labs	Form 4	Other acquisition or disposition	--	--	4,330
Dec 17, 2008	GOLDBERG MURRAY A SVP F&A, CFO, Treas, & Ast Sec Trans History: 645	SVP F&A, CFO, Treas, & Ast Sec	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	5,952	--	5,952
Dec 17, 2008	GOLDBERG MURRAY A SVP F&A, CFO, Treas, & Ast Sec Trans History: 645	SVP F&A, CFO, Treas, & Ast Sec	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	31,548	--	31,548
Dec 17, 2008	KOLINSKI STUART SVP, Gen Counsel & Secretary Trans History: 117	SVP, Gen Counsel & Secretary	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	5,952	--	5,952
Dec 17, 2008	KOLINSKI STUART SVP, Gen Counsel & Secretary Trans History: 117	SVP, Gen Counsel & Secretary	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	19,048	--	19,048
Dec 17, 2008	McCorkle Douglas S VP, Controller and Asst. Treas Trans History: 372	VP, Controller and Asst. Treas	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	5,000	--	5,000
Dec 17, 2008	McCorkle Douglas S VP, Controller and Asst. Treas Trans History: 372	VP, Controller and Asst. Treas	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	15,000	--	15,000
Dec 17, 2008	Powchik Peter SVP, Clinical Development Trans History: 208	SVP, Clinical Development	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	5,000	--	5,000

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media